TNX-102 SL 5.6 mg

DRUG2 trials

Sponsors

Tonix Pharmaceuticals, Inc.

Conditions

Healthy SubjectsPTSD

Phase 1

Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules

CompletedNCT03443960

Tonix Pharmaceuticals, Inc.Healthy Subjects

Start: 2018-01-29End: 2018-04-09Updated: 2018-04-24

Phase 3

A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD

CompletedNCT03508700

Tonix Pharmaceuticals, Inc.PTSD

Start: 2018-04-19End: 2019-09-30Updated: 2025-02-05